BPO 0.00% 0.3¢ bioprospect limited

announcement, page-2

  1. 3,958 Posts.
    lightbulb Created with Sketch. 492
    In my opinion, the reason why the price did not move any higher was because there was no mention of any financial impact to BPO.
    It could take quite a while before this agreement results in an royalty payments to BPO, so in reference to this, I would be patient.

    What I am becoming impatient about is results of field trials for Qcide. The company said they expected these in sept and oct this year, and still nothing. With the warm weather in Australia over the last couple of months, they would surely have enough of an idea as to the prospects relating to Qcide, but as yet they have not released anything.

    But at least over the last week there has been volume....
watchlist Created with Sketch. Add BPO (ASX) to my watchlist

Currently unlisted public company.

arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.